Original Article|Articles in Press

Evaluation of the meropenem dosage and administration schedule in patients with bacteremia initial therapy

Published:April 22, 2023DOI:



      The standard meropenem (MEPM) regimen allowed by insurance in Japan is 0.5 g two or three times a day. Differences in dosages and administration schedules in Japan were evaluated.


      Patients with bacteremia for whom MEPM was used as the initial treatment at our institution between 2016 and 2021 were included. We retrospectively investigated patients classified into two groups: those treated according to severe infections (high-dose groupand others (low-dose group). After propensity score matching, we compared the probability of achieving free drug blood levels above the minimum inhibitory concentration (MIC) in 24 h (%fT > MIC) and outcomes.


      The probability of 100% fT > MIC was significantly higher in the high-dose group (96.4% vs 74.5%, odds ratio [OR] = 0.3, 95% confidence interval [CI] = 0.2–0.4, P = < 0.001). Regarding outcomes, the 30-day mortality rate was significantly lower in the high-dose group (1.4% vs. 11.4%, OR = 8.0, 95% CI = 1.5–43.7, P = 0.019).


      To improve outcomes in patients with bacteremia treated with MEPM, support for appropriate antimicrobial use is necessary for compliance with the dosage and administration schedule according to severe infections in initial treatment.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Infection and Chemotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rhomberg P.R.
        • Jones R.N.
        Summary trends for the meropenem yearly susceptibility test information collection program: a 10-year experience in the United States (1999-2008).
        Diagn Microbiol Infect Dis. 2009; 65: 414-426
        • Steffens N.A.
        • Zimmermann E.S.
        • Nichelle S.M.
        • Brucker N.
        Meropenem use and therapeutic drug monitoring in clinical practice: a literature review.
        J Clin Pharm Therapeut. 2021; 46: 610-621
        • Cockcroft D.W.
        • Gault H.
        Prediction of creatinine clearance from serum creatinine.
        Nephron. 1976; 16: 31-41
        • Gilbert D.N.
        • Moellering Jr., R.C.
        • Eliopoulos G.M.
        • Henry F.
        • Saag M.S.
        The Sanford Guide to antimicrobial therapy.
        52th edn. Antimicrobial Therapy, Sperryville, VA2022
        • CLSI
        Performance standards for antimicrobial susceptibility testing.
        M100 32nd Edition. Clinical and Laboratory Standards Institute, Wayne, PA2022
        • The Japanese society for clinical microbiology
        Collaborative proposal by four societies problems of enterobacteriaceae bacteria showing a tendency to carbapenem resistance (2017) - importance of infection control for carbapenemase-producing bacteria.
        • Craig W.A.
        Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.
        Clin Infect Dis. 1998; 26: 1-10
        • Ikawa K.
        • Morikawa N.
        • Ikeda K.
        • Ohge H.
        • Sueda T.
        • Taniwaki M.
        • et al.
        Pharmacokinetic-pharmacodynamic target attainment analysis of meropenem in Japanese adult patients.
        J Infect Chemother. 2010; 16: 25-32
        • Iba K.
        Pharmacokinetics of [14C] meropenem in dogs and monkeys.
        Jpn J Chemother. 1992; 40: 145-153
        • Scharf C.
        • Paal M.
        • Schroeder I.
        • Vogeser M.
        • Draenert R.
        • Irlbeck M.
        • et al.
        Therapeutic drug monitoring of meropenem and piperacillin in critical illness—experience and recommendations from one year in routine clinical practice.
        Antibiotics. 2020; 9: 131
        • Burger R.
        • Guidi M.
        • Calpini V.
        • Lamoth F.
        • Decosterd L.
        • Robatel C.
        • et al.
        Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
        J Antimicrob Chemother. 2018; 73: 3413-3422
        • Udy A.A.
        • Varghese J.M.
        • Altukroni M.
        • Briscoe S.
        • McWhinney B.C.
        • Ungerer J.P.
        • et al.
        Subtherapeutic initial β-lactam concentrations in select critically ill patients.
        Chest. 2012; 142: 30-39
        • Abdulla A.
        • Dijkstra A.
        • Hunfeld N.G.
        • Endeman H.
        • Bahmany S.
        • Ewoldt T.M.
        • et al.
        Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).
        Crit Care. 2020; 24: 1-12
        • Wong G.
        • Briscoe S.
        • McWhinney B.
        • Ally M.
        • Ungerer J.
        • Lipman J.
        • et al.
        Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures.
        J Antimicrob Chemother. 2018; 73: 3087-3094
        • Dulhunty J.M.
        • Roberts J.A.
        • Davis J.S.
        • Webb S.A.
        • Bellomo R.
        • Gomersall C.
        • et al.
        Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.
        Clin Infect Dis. 2013; 56: 236-244
        • Kuti J.L.
        • Ong C.
        • Lo M.
        • Melnick D.
        • Soto N.
        • Nicolau D.P.
        Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infection.
        Int J Antimicrob Agents. 2006; 28: 62-68
        • Drusano G.L.
        Prevention of resistance, a goal for dose selection for antimicrobial agents.
        Clin Infect Dis. 2003; 36: S42-S50
        • Oda K.
        Development of software for antimicrobial PK/PD simulation incorporating Monte Carlo simulation based on Microsoft® office excel.
        Jpn J Pharmaceut Health Care Sci. 2011; 37: 335-344
        • Kanda Y.
        Investigation of the freely available easy-touse software ‘EZR’for medical statistics.
        Bone Marrow Transplant. 2013; 48: 452-458
        • Kawanami T.
        • Mukae H.
        • Noguchi S.
        • Yamasaki K.
        • Akata K.
        • Ishimoto H.
        • et al.
        Efficacy and safety of meropenem (3 g daily) in Japanese patients with refractory respiratory infections.
        J Infect Chemother. 2014; 20: 768-773
        • Frei C.R.
        • Wiederhold N.
        • Burgess D.
        Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic–pharmacodynamic models with Monte Carlo simulation.
        J Antimicrob Chemother. 2008; 61: 621-628
        • Kollef M.H.
        • Sherman G.
        • Ward S.
        • Fraser V.J.
        Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.
        Chest. 1999; 115: 462-474
        • Kollef M.H.
        Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients.
        Clin Infect Dis. 2000; 31: S131-S138
        • Weinstein M.P.
        • Towns M.L.
        • Quartey S.M.
        • Mirrett S.
        • Reimer L.G.
        • Parmigiani G.
        • et al.
        The clinical significance of positive blood cultures in the 1990s, a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults.
        Clin Infect Dis. 1997; 24: 584-602
        • Leibovici L.
        • Shraga I.
        • Drucker M.
        • Konigsberger H.
        • Samra Z.
        • Pitlik S.D.
        The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection.
        J Intern Med. 1998; 244: 379-386
        • Evans L.
        • Rhodes A.
        • Alhazzani W.
        • Antonelli M.
        • Coopersmith C.M.
        • French C.
        • et al.
        Surviving Sepsis Campaign Guidelines Committee. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock.
        Crit Care Med. 2021; 49 (2021): 1063-1143
        • Gradel K.O.
        • Jensen U.S.
        • Schønheyder H.C.
        • Østergaard C.
        • Knudsen J.D.
        • Wehberg S.
        • et al.
        Impact of appropriate empirical antibiotic treatment on recurrence and mortality in patients with bacteraemia: a population-based cohort study.
        BMC Infect Dis. 2017; 17: 1-9
        • Roberts J.A.
        • Abdul-Aziz M.H.
        • Davis J.S.
        • Dulhunty J.M.
        • Cotta M.O.
        • Myburgh J.
        • et al.
        Continuous versus intermittent β-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials.
        Am J Respir Crit Care Med. 2016; 194: 681-691
        • Vardakas K.Z.
        • Voulgaris G.L.
        • Maliaros A.
        • Samonis G.
        • Falagas M.E.
        Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials.
        Lancet Infect Dis. 2018; 18: 108-120
        • Schoenenberger-Arnaiz J.A.
        • Ahmad-Diaz F.
        • Miralbes-Torner M.
        • Aragones-Eroles A.
        • Cano-Marron M.
        • Palomar-Martinez M.
        Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.
        Eur J Hosp Pharm. 2020; 27: e30-e35